Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gennaro Colella

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Cellular and Molecular Medicine|July 19, 2012
Is PDGFR an important target for E-3810?Giovanna Damia, Gennaro Colella, Gabriella Camboni, et al.
The Journal of Clinical Investigation|January 24, 2002
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosisMarzia Pennati, Gennaro Colella, Marco Folini, et al.
The Journal of Investigative Dermatology|March 22, 2003
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expressionMarzia Pennati, Mara Binda, Gennaro Colella, et al.
Molecular & Cellular Proteomics : MCP|April 4, 2014
Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810Mara Colzani, Roberta Noberini, Mauro Romanenghi, et al.
Cancer Research|January 8, 2011
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical modelsEzia Bello, Gennaro Colella, Valentina Scarlato, et al.
Molecular Cancer Therapeutics|December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenograftsEzia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Oncogene|January 16, 2004
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cellsMarzia Pennati, Mara Binda, Gennaro Colella, et al.
Cancer Gene Therapy|March 30, 2022
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesotheliomaRihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Cellular and Molecular Medicine|July 19, 2012
Is PDGFR an important target for E-3810?Giovanna Damia, Gennaro Colella, Gabriella Camboni, et al.
The Journal of Clinical Investigation|January 24, 2002
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosisMarzia Pennati, Gennaro Colella, Marco Folini, et al.
The Journal of Investigative Dermatology|March 22, 2003
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expressionMarzia Pennati, Mara Binda, Gennaro Colella, et al.
Molecular & Cellular Proteomics : MCP|April 4, 2014
Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810Mara Colzani, Roberta Noberini, Mauro Romanenghi, et al.
Cancer Research|January 8, 2011
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical modelsEzia Bello, Gennaro Colella, Valentina Scarlato, et al.
Molecular Cancer Therapeutics|December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenograftsEzia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Oncogene|January 16, 2004
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cellsMarzia Pennati, Mara Binda, Gennaro Colella, et al.
Cancer Gene Therapy|March 30, 2022
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesotheliomaRihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, et al.
Pageof 1